Andrea Lobo,  —

The case of a 72-year-old man who developed myasthenia gravis (MG) and myocarditis, or inflammation of the heart, following chemoimmunotherapy for gastric cancer that included sintilimab showcases the need to better understand how this treatment can induce the immune disorder, said researchers in China. Sintilimab is a type of…

Blood levels of specific antibodies that target the muscle-specific tyrosine kinase (MuSK) may be biomarkers of disease severity and treatment response in people with myasthenia gravis (MG) who are positive for anti-MuSK antibodies. A study finds that high levels of MuSK-IgG4 — an anti-MuSK antibody subclass – were associated…

Johnson & Johnson has submitted an application to the European Medicines Agency (EMA) seeking approval of nipocalimab to treat people with generalized myasthenia gravis (gMG). The request includes gMG patients who are positive for MG-causing autoantibodies targeting acetylcholine receptors (AChRs), muscle-specific tyrosine (MuSK), and low-density lipoprotein…

Surgical removal of the thymus, called a thymectomy, may significantly ease the neurological symptoms of patients older than 65 who have myasthenia gravis (MG) and a thymus tumor, according to a new study from researchers in Italy. Overall, nearly 90% of older individuals undergoing thymectomy showed a neurological…

UCB’s injection therapy Zilbrysq (zilucoplan) has gained approval in Canada for treating adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR). The decision by Health Canada was supported by results from the Phase 3 RAISE trial (NCT04115293), in which the…

Treatment with nipocalimab led to significant reductions in disease severity among people with generalized myasthenia gravis (gMG), as assessed by a drop in the MG Activities of Daily Living (MG-ADL) score, according to top-line data from a pivotal Phase 3 trial. Findings from the trial, dubbed VIVACITY-MG3…

Treatment with Keytruda (pembrolizumab), an immune checkpoint inhibitor (ICI) used to treat cancer, may trigger myasthenia gravis (MG), according to a recent case report. The patient, a 73-year-old man with a previous history of skin and prostate cancer, developed symptoms of MG and myositis — a disease in which…

NMD Pharma announced the dosing of the first patient in a Phase 2b clinical trial of NMD670, its investigational oral therapy for generalized myasthenia gravis (gMG). The SYNAPSE-MG trial (NCT06414954), recently cleared by the U.S. Food and Drug Administration (FDA), is assessing the treatment’s safety and…

A greater reduction in disease severity a month after surgery to remove the thymus gland in myasthenia gravis (MG) patients without a thymus tumor is linked with lower disease recurrence, a study in China suggests. Patients with a reduction of at least 36.7% in the Quantitative Myasthenia Gravis score…

Blood levels of interleukin-41 (IL-41) — a signaling molecule involved in immune responses — are found to be significantly elevated in people with myasthenia gravis (MG), and associated with disease severity and inflammatory markers, a study from China reports. These findings indicate “IL-41 may be essential to the [disease]…